SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Panacos Pharmaceuticals (PANC) -- Ignore unavailable to you. Want to Upgrade?


To: kenhott who wrote (42)12/12/2007 7:46:28 AM
From: idos  Read Replies (2) | Respond to of 53
 
PANC is currently analyzing possible correlations between factors such as protein binding, concurrent medications, or viral phenotype and response to bevirimat (I would think resistance).

They plan to test bevirimat in a 400mg and they have the oral
solutions in development.

So I guess the answer to your question- "How long are they going to hit their heads against this wall?" is: As long as they have cash.